Overview

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
0
Participant gender:
All
Summary
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Concert Pharmaceuticals
Criteria
Inclusion Criteria:

- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion Criteria:

- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
keratosis

- Females who are nursing, pregnant, or planning to become pregnant while in the study,
and for 30 days after last dose of study medication

- Donation of blood at any point throughout the study and for 30 days after last dose of
study medication